NCT06220318 2025-11-28
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
Fujian Haixi Pharmaceuticals Co., Ltd.
Phase 1/2 Active not recruiting
Fujian Haixi Pharmaceuticals Co., Ltd.
Innovent Biologics (Suzhou) Co. Ltd.